U.S. President Barack Obama is this week hosting fifty
African leaders in Washington D.C. It's an event the
White House has dubbed "historic," and it's designed
to promote trade and investment.
But as the summit launched Monday, the deadliest
Ebola outbreak in history was intensifying in Western
Africa. Two VIPs -- Nobel Peace prize recipient and
president of Liberia Ellen Johnson Sirleaf, and her Serra
Leone counterpart Ernest Bai Koroma -- canceled their
trips.
Instead, they chose to stay in their home countries and
deal with a health crisis that has so far claimed nearly
900 lives. It has also dragged on the region's
economies, and the economic pain is expected to get
worse.
At the summit's opening day, the World Bank pledged
$200 million to contain the epidemic. The World Health
Organization and West African nations hit by the
outbreak have also poured $100 million into plans to
try and contain it.
But the Ebola virus has hit some of West Africa's most
vulnerable economies, and poorest rural areas. The
economic growth of Guinea, where more than 300
people have died after being infected by the virus, is
now expected by the World Bank and IMF to slow to
3.5%, from 4.5%.
Is the world investing in prevention?
Peter Piot, a director at the London School of Hygiene &
Tropical Medicine, helped discover the virus nearly four
decades ago. He says many unknowns remain around
treatment, how Ebola causes death and how this can
be prevented.
Thus far, there is no proven treatment and no vaccine
for Ebola, although one experimental drug has
attracted interest after apparently saving the lives of
two American missionaries infected.
In March, America's National Institutes of Health
awarded a five-year, $28 million grant to establish a
collaboration between researchers from fifteen
institutions who were working to fight Ebola.
Other trials are also taking place, including by Tekmira,
a Vancouver-based company that has a $140 million
contract with the U.S. Department of Defense to
develop an Ebola drug.
P
Sunday, August 10, 2014
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment